Open Peer Review on Qeios

Personalized ALL-specific Multi-HLAbinding Peptide Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>Personalized ALL-specific Multi-HLA-binding Peptide Vaccine</u>. NCI Thesaurus. Code C159601.

An individualized peptide-based cancer vaccine comprised of three to five human leukocyte antigen (HLA) binding tumor-specific peptides obtained from the autologous mutated proteins from the tumor cells of patients with acute lymphoblastic leukemia (ALL), with potential immunomodulating and antineoplastic activity. Upon intradermal administration of the personalized multi-HLA-binding peptide vaccine, the peptides may induce a tumor-specific cytotoxic T-lymphocyte (CTL) response against the peptides that are expressed by the tumor cells.